» Articles » PMID: 35035875

Lipid Ratios and Obesity Indices Are Effective Predictors of Metabolic Syndrome in Women with Polycystic Ovary Syndrome

Abstract

Background: Insulin resistance (IR) is common in women with polycystic ovary syndrome (PCOS). Metabolic syndrome (MS) involves IR, arterial hypertension, dyslipidemia, and visceral fat accumulation. Therefore, fatness indices and blood lipid ratios can be considered as screening markers for MS. Our study aimed to evaluate the predictive potential of selected indirect metabolic risk parameters to identify MS in PCOS.

Methods: This cross-sectional study involved 596 women aged 18-40 years, including 404 PCOS patients diagnosed according to the Rotterdam criteria and 192 eumenorrheic controls (CON). Anthropometric and blood pressure measurements were taken, and blood samples were collected to assess glucose metabolism, lipid parameters, and selected hormone levels. Body mass index (BMI), waist-to-height ratio (WHtR), homeostasis model assessment for insulin resistance index (HOMA-IR), visceral adiposity index (VAI), lipid accumulation product (LAP), non-high-density lipoprotein cholesterol (non-HDL-C), and triglycerides-to-HDL cholesterol ratio (TG/HDL-C) were calculated. MS was assessed using the International Diabetes Federation (IDF) and the American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI) criteria.

Results: MS prevalence was significantly higher in PCOS CON. Patients with both MS and PCOS had more unfavorable anthropometric, hormonal, and metabolic profiles those with neither MS nor PCOS and CON with MS. LAP, TG/HDL-C, VAI, and WHtR were the best markers and strongest indicators of MS in PCOS, and their cut-off values could be useful for early MS detection. MS risk in PCOS increased with elevated levels of these markers and was the highest when TG/HDL-C was used.

Conclusions: LAP, TG/HDL-C, VAI, and WHtR are representative markers for MS assessment in PCOS. Their predictive power makes them excellent screening tools for internists and enables acquiring accurate diagnoses using fewer MS markers.

Citing Articles

Perspective from NHANES data: synergistic effects of visceral adiposity index and lipid accumulation products on diabetes risk.

He J, Chen L Sci Rep. 2025; 15(1):258.

PMID: 39747273 PMC: 11696142. DOI: 10.1038/s41598-024-84034-7.


The waist-to-height ratio is a good predictor for insulin resistance in women with polycystic ovary syndrome.

Zhu M, Wang K, Feng J, Liu Y, Guan M, Wang Y Front Endocrinol (Lausanne). 2024; 15:1502321.

PMID: 39717101 PMC: 11664359. DOI: 10.3389/fendo.2024.1502321.


MicroRNAs as Biomarkers for Metabolic Disorders in Polycystic Ovary Syndrome (PCOS): A Review.

Dymanowska I, Frankowska K, Krawczyk A, Kociuba J, Gil-Kulik P, Banaszewska B Med Sci Monit. 2024; 30:e946480.

PMID: 39709519 PMC: 11670786. DOI: 10.12659/MSM.946480.


Comparison of atherogenic indices for predicting the risk of metabolic syndrome in Southwest Iran: results from the Hoveyzeh Cohort Study (HCS).

Babaahmadi-Rezaei H, Raeisizadeh M, Zarezade V, Noemani K, Mashkournia A, Ghaderi-Zefrehi H Diabetol Metab Syndr. 2024; 16(1):112.

PMID: 38783371 PMC: 11112906. DOI: 10.1186/s13098-024-01349-1.


Utility of Visceral Adiposity Index and Lipid Accumulation Products to Define Metabolically-Unhealthy Polycystic Ovary Syndrome in Asian Indian Women - A Cross Sectional Study.

Shreenidhi R, Mahey R, Rajput M, Cheluvaraju R, Upadhyay A, Sharma J J Hum Reprod Sci. 2024; 17(1):50-57.

PMID: 38665608 PMC: 11041319. DOI: 10.4103/jhrs.jhrs_14_24.


References
1.
Costa E, DE Sa J, Soares E, Lemos T, Maranhao T, Azevedo G . Anthropometric indices of central obesity how discriminators of metabolic syndrome in Brazilian women with polycystic ovary syndrome. Gynecol Endocrinol. 2011; 28(1):12-5. DOI: 10.3109/09513590.2011.583956. View

2.
Vekic J, Zeljkovic A, Stefanovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V . Obesity and dyslipidemia. Metabolism. 2018; 92:71-81. DOI: 10.1016/j.metabol.2018.11.005. View

3.
Guleken Z, Bulut H, Bulut B, Depciuch J . Assessment of the effect of endocrine abnormalities on biomacromolecules and lipids by FT-IR and biochemical assays as biomarker of metabolites in early Polycystic ovary syndrome women. J Pharm Biomed Anal. 2021; 204:114250. DOI: 10.1016/j.jpba.2021.114250. View

4.
Bronczyk-Puzon A, Jagielski P, Kulik-Kupka K, Koszowska A, Nowak J, Zubelewicz-Szkodzinska B . Usefulness of a new anthropometric indicator - VAI (Visceral Adiposity Index) in the evaluation of metabolic and hormonal disorders in women with polycystic ovary syndrome. Adv Clin Exp Med. 2017; 26(5):825-828. DOI: 10.17219/acem/61100. View

5.
Behboudi-Gandevani S, Ramezani Tehrani F, Cheraghi L, Azizi F . Could "a body shape index" and "waist to height ratio" predict insulin resistance and metabolic syndrome in polycystic ovary syndrome?. Eur J Obstet Gynecol Reprod Biol. 2016; 205:110-4. DOI: 10.1016/j.ejogrb.2016.08.011. View